Celgene gets European nod for Abraxane in pancreatic cancer; Sinclair buys Obvieline Labs for its Perfectha derm gel;

@FiercePharma: Move over, BigPharma. Valeant's CEO plans to elbow his way in. More | Follow @FiercePharma

@EricPFierce: China clears vaccinemakers in deaths then shuts some down. Story | Follow @EricPFierce

@CarlyHFierce: Hi-Tech Pharmacal CEO to reap almost $85M from its sale to Akorn. Article | Follow @CarlyHFierce

> Celgene's ($CELG) Abraxane won a new indication in Europe as a first-line treatment for patients with metastatic pancreatic cancer. Release

> Sinclair IS Pharma acquired global rights to a dermatology gel, Perfectha, by buying its maker, Obvieline Laboratories. Report

> Mylan ($MYL) bought the rights to a respiratory drug from Pfizer ($PFE) and says the product is ready to submit to the FDA for approval. Report

> Poor people with diabetes are more likely to go to the hospital with low blood sugar when their food budgets are tight, a study found. Report (sub. req.)

Medical Device News

@FierceMedDev: BD trades $40M for diagnostics partner Alverix. More | Follow @FierceMedDev

@MichaelGFierce: How a single nanoparticle delivers two drugs separately to kill cancer cells. More from FierceDrugDelivery | Follow @MichaelGFierce

@GalenMoore: The FDA warns Abbott's faulty blood glucose test strips could lead to serious injury or death. Story | Follow @GalenMoore

> Sapheon hauls in $10M as it works toward FDA approval for a varicose vein device. Item

> Stryker teams with Samsung's NeuroLogica on a portable CT scanner. More

> FDA slaps its most serious label on Abbott's diabetes recall. Article

> Medtronic spends $160M on Tyrx and its antibacterial envelopes. News

Biotech News

@FierceBiotech: Texas' Bellicum gets $15M to expand work on gene 'switch' tech. More | Follow @FierceBiotech

@JohnCFierce: In search for success, R&D teams are overcrowding small drug franchises. Story | Follow @JohnCFierce

@DamianFierce: Friendly reminder that there were 27 drugs approved last year and we wrote, like, 1,000 words on each. Report | Follow @DamianFierce

@EmilyMFierce: Alcohol-addicted rats treated with optogenetics stop drinking. More from FierceBiotech Research | Follow @EmilyMFierce

> Epizyme shares rocket up on news of $29M milestone awards. More

> Neurocrine shares soar with a promising second take on a PhIIb drug. Story

> Lilly is carving up to $1B out of its struggling R&D division. News

Biotech Research News

> Cancer Research UK will repurpose an AstraZeneca asthma drug for kidney cancer. More

> 6 U.S. institutions receive $540M in cancer research funds. Story

> Astellas, ClearPath team up to develop vaccines for infectious diseases. Article

> Gene defect that blocks insulin release in mice may cause Type 2 diabetes. News

> Alcohol-addicted rats treated with optogenetics stop drinking. Report

> Discovery of immune boosters' role in TB control could help develop new therapeutics. Item

Pharma Manufacturing News

> $1B deal pushes GE further into biologics manufacturing. More

> Pall moves into single-use bioreactors with deal to buy ATMI LifeSciences. Article

> Chinese heparin maker Hepalink buying U.S.-based SPL. Story

> China clears vaccine makers in deaths then shuts some down. News

> EMA makes inspection reports public. Item

> Baxter issues another recall after particulate found in products. Report

And Finally... A study found that meditation can deliver small improvements in anxiety and depression. Report

 

Suggested Articles

Long-time trend watcher and marketer Rohit Bhargava challenged pharma marketers to adopt new habits to become non-obvious thinkers.

Samsung Biologics opened the doors to its first-ever US CDO R&D Center in San Francisco.

When the COVID-19 pandemic began, early fears of shortages of pharmaceutical supplies and drugs were quickly abated by a responsive supply chain.